FOXO4
FOXO4-DRI
A retro-inverso peptide: the sequence of a FOXO4 forkhead-domain fragment written backwards and built entirely from D-amino acids, a construction that presents a similar side-chain arrangement while resisting proteases. It is designed to interfere with the interaction between FOXO4 and p53 — a protein-protein interface rather than a receptor.
No registered human study names FOXO4-DRI as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains FOXO4-DRI. 19 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names FOXO4-DRI; the registry search is fuzzy, so every match is re-checked. None of this says whether FOXO4-DRI works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
19
Readership
1,079
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of FOXO4-DRI in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What FOXO4-DRI is, and what it has been studied for
FOXO4-DRI is tracked here.
No registered trial names FOXO4-DRI as an intervention, so there is no condition it has been formally studied in. It does have a literature: 19 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying FOXO4-DRI?
Papers published each year that name FOXO4-DRI in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 3 | 0 | Yes |
| 2018 | 2 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 1 | 0 | Yes |
| 2021 | 2 | 0 | Yes |
| 2022 | 3 | 0 | Yes |
| 2023 | 2 | 0 | Yes |
| 2024 | 2 | 0 | Yes |
| 2025 | 3 | 0 | Yes |
| 2026 | 4 | 0 | No |
19 papers between 2017 and 2026. A paper counts when “FOXO4-DRI” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on FOXO4-DRI
19 indexed papers name FOXO4-DRI in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
- FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
Collected 2026-08-02from PubMed, phrase-matched on “FOXO4-DRI” in title and abstract. Run the same search.
About FOXO4-DRI
A retro-inverso peptide: the sequence of a FOXO4 forkhead-domain fragment written backwards and built entirely from D-amino acids, a construction that presents a similar side-chain arrangement while resisting proteases. It is designed to interfere with the interaction between FOXO4 and p53 — a protein-protein interface rather than a receptor.
- Also known as
- FOXO4-D-Retro-Inverso
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.